Skip to main content

Advertisement

SpringerLink
Log in

Comparison of effects of tamsulosin and silodosin on subfoveal choroidal thickness and pupil size diameters in patients with prostatic hyperplasia

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the effects of selective α-1 adrenoceptor antagonists on subfoveal choroidal thickness (SFCT) and pupil diameter size (PDS).

Methods

This prospective study included 87 patients diagnosed with benign prostatic hyperplasia who were treated with tamsulosin hydrochloride (n = 41) or silodosin (n = 46). SFCT measurements were obtained using spectral domain optic coherence tomography (SD-OCT), and PDS measurements were obtained under mesopic, photopic and scotopic conditions using a photography-based topography system. SFCT and PDS were evaluated at baseline and 3-, 6- and 12-mo follow-ups.

Results

The initial mean SFCT was 270.53 ± 21.48 µm in tamsulosin group and 271.95 ± 24. 73 in silodosin group (P = 0.078). There was no statistically significant change in SFCT at the 3-mo visit. At the 6-mo follow-up, the mean SFCT was 281.34 ± 22.09 µm in tamsulosin group and 272.5 ± 22.4 µm in silodosin group. At the 12th month, the mean SFCT in tamsulosin group was 290.80 ± 17.27 µm, and it was 270.80 ± 13.14 µm in silodosin group. There was statistically significant difference in at 6th and 12-mo visits (P = 0.014 and P = 0.00). During the follow-up, both drugs induced a similar significant decrease in PDS under all conditions.

Conclusions

Tamsulosin hydrochloride caused a significant increase in SFCT. In contrast, SFCT did not increase in silodosin group. The decreases in PDS achieved using both drugs were similar. This should be kept in mind when choroidal disease and its response to treatment are followed by CT imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr et al (2019) Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 8(5):529–539. https://doi.org/10.21037/tau.2019.10.01 (PubMed PMID: 31807429)

    Article  PubMed  PubMed Central  Google Scholar 

  2. Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, Medina-López R, Ruiz-Cerdá JL, Rodríguez-Rubio F et al (2016) Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study. Int Urol Nephrol 48(5):645–656

    Article  Google Scholar 

  3. Erkoç M, Beşiroğlu H (2020) Comparison of bipolar TURP and monopolar TURP patients who underwent surgery due to benign prostatic hyperplasia. Eur Arc Med Res 36(1):8–11

    Article  Google Scholar 

  4. Yonguc T, Sen V, Bozkurt HI, Aydin ME, Polat S, Yarimoglu S (2019) Impact of chronic constipation on lower urinary tract symptoms and uroflowmetry parameters in men. J Urolo Surg 6(4):308–313. https://doi.org/10.4274/jus.galenos.2019.2612(PubMedPMID:WOS:000501997300007)

    Article  Google Scholar 

  5. Aydogan TB, Kaya E, Gazel E, Yalcin S, Aybal HC, Tunc L (2019) Impact of metabolic syndrome on pre- and postoperative parameters in patients undergoing a HoLEP surgery. Turkish J Urol 45:98–103. https://doi.org/10.5152/tud.2019.88027 (PubMedPMID:WOS:000502637300017)

    Article  Google Scholar 

  6. Gürbüz C, Drake MJ (2019) Where can urodynamic testing help assess male lower urinary tract symptoms? Turkish J Urol 45(3):157

    Article  Google Scholar 

  7. Verim L, Yıldırım A, Peltekoğlu E, Başok EK, Keskin SK, Çanakcı C (2015) Evaluation of the lower urinary tract symptoms and erectile dysfunction with uroflowmetry, IPSS and IIEF questioniares. J Urol Surg 2(2):75–80

    Article  Google Scholar 

  8. Yap TL, Brown C, Cromwell DA, Van Der Meulen J, Emberton M (2009) The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int 104(8):1104–1108. https://doi.org/10.1111/j.1464-410X.2009.08497.x

    Article  PubMed  Google Scholar 

  9. Bishr M, Boehm K, Trudeau V, Tian Z, Dell’Oglio P, Schiffmann J et al (2016) Medical management of benign prostatic hyperplasia: results from a population-based study. Can Urol Assoc J 10(1–2):55–59. https://doi.org/10.5489/cuaj.3058 (PubMed PMID: 26977208)

    Article  PubMed  PubMed Central  Google Scholar 

  10. Michel MC (2010) The Forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: α-blockers in the treatment of male voiding dysfunction—How do they work and why do they differ in tolerability? J Pharmacol Sci 112(2):151–157. https://doi.org/10.1254/jphs.09R15FM

    Article  CAS  PubMed  Google Scholar 

  11. Oelke M, Gericke A, Michel MC (2014) Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf 13(9):1187–1197. https://doi.org/10.1517/14740338.2014.936376

    Article  CAS  PubMed  Google Scholar 

  12. Suzuki F, Taniguchi T, Nakamura S, Akagi Y, Kubota C, Satoh M et al (2002) Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes. Br J Pharmacol 135(3):600–608. https://doi.org/10.1038/sj.bjp.0704503 (PubMed PMID: 11834607)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lunacek A, Mohamad Al-Ali B, Radmayr C, Weber M, Horninger W, Findl O et al (2018) Ten years of intraoperative floppy iris syndrome in the era of α-blockers. Cent European J Urol 71(1):98–104. https://doi.org/10.5173/ceju.2017.1234 (PubMed PMID: 29732214)

    Article  CAS  PubMed  Google Scholar 

  14. Sezer T, Altınışık M, Koytak İA, Özdemir MH (2016) The choroid and optical coherence tomography. Turk J Ophthalmol. 46(1):30–7. https://doi.org/10.4274/tjo.10693 (PubMed PMID: 27800255)

    Article  PubMed  PubMed Central  Google Scholar 

  15. Shibata K, Foglar R, Horie K, Obika K, Sakamoto A, Ogawa S et al (1995) KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 48(2):250–258

    CAS  PubMed  Google Scholar 

  16. Chang DF, Campbell JR (2005) Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31(4):664–673. https://doi.org/10.1016/j.jcrs.2005.02.027

    Article  PubMed  Google Scholar 

  17. Chatterjee S, Agrawal D (2017) Silodosin-associated intraoperative floppy iris syndrome. Indian J Ophthalmol 65(6):538–539. https://doi.org/10.4103/ijo.IJO_704_16

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ipekci T, Akin Y, Hoscan B, Tunckiran A (2015) Intraoperative floppy iris syndrome associated with silodosin. Acta Ophthalmologica 93(4):e306-e. https://doi.org/10.1111/aos.12549

    Article  Google Scholar 

  19. Goseki T, Ishikawa H, Ogasawara S, Mashimo K, Nemoto N, Taguchi Y et al (2012) Effects of tamsulosin and silodosin on isolated albino and pigmented rabbit iris dilators: possible mechanism of intraoperative floppy-iris syndrome. J Cataract Refract Surg 38(9):1643–1649. https://doi.org/10.1016/j.jcrs.2012.05.025

    Article  PubMed  Google Scholar 

  20. Patil PN (2004) Parameters of drug antagonism: re-examination of two modes of functional competitive drug antagonism on intraocular muscles. J Pharm Pharmacol 56(8):1045–1053. https://doi.org/10.1211/0022357043978

    Article  CAS  PubMed  Google Scholar 

  21. Dogan M, Kutluksaman B, Keles I, Karalar M, Halat AO (2017) The effects of systemic alfuzosin and tamsulosin hydrochloride on choroidal thickness and pupil diameter sizes in cases with benign prostatic hyperplasia. Curr Eye Res 42(12):1638–1643. https://doi.org/10.1080/02713683.2017.1359306

    Article  CAS  PubMed  Google Scholar 

  22. Sari E, Sogutlu Sari E, Yazici A, Koç A, Bulbul E, Koytak A et al (2015) The effect of systemic tamsulosin hydrochloride on choroidal thickness measured by enhanced depth imaging spectral domain optical coherence tomography. Curr Eye Res 40(10):1068–1072. https://doi.org/10.3109/02713683.2014.971935

    Article  CAS  PubMed  Google Scholar 

  23. Nickla DL, Wallman J (2010) The multifunctional choroid. Prog Retin Eye Res 29(2):144–168. https://doi.org/10.1016/j.preteyeres.2009.12.002 (PubMed PMID: 20044062; PubMed Central PMCID: PMC2913695)

    Article  PubMed  Google Scholar 

  24. Ölçücü MT, Teke K, Yildirim K, Toğaç M, Işık B, Yilmaz YC (2020) Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: a prospective study. Int Braz J Urol 46(2):185–193

    Article  Google Scholar 

  25. Reiner A, Zagvazdin Y, Fitzgerald MEC (2003) Choroidal blood flow in pigeons compensates for decreases in arterial blood pressure. Exp Eye Res 76(3):273–282. https://doi.org/10.1016/S0014-4835(02)00316-0

    Article  CAS  PubMed  Google Scholar 

  26. Bouteleux V, Kodjikian L, Mendes M, Agard E, Machkour-Bentaleb Z, El-Chehab H et al (2019) Increased choroidal thickness: a new feature to monitor age-related macular degeneration recurrence. Graefes Arch Clin Exp Ophthalmol 257(4):699–707. https://doi.org/10.1007/s00417-018-04216-8

    Article  PubMed  Google Scholar 

  27. Chen Y, Palczewska G, Mustafi D, Golczak M, Dong Z, Sawada O et al (2013) Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration. J Clin Inves 123(12):5119–34. https://doi.org/10.1172/jci69076 (PubMed PMID: 24231350)

    Article  CAS  Google Scholar 

  28. Orban T, Leinonen H, Getter T, Dong Z, Sun W, Gao S et al (2018) A combination of G protein-coupled receptor modulators protects photoreceptors from degeneration. J Pharmacol Exp Ther 364(2):207–20. https://doi.org/10.1124/jpet.117.245167 (PubMed PMID: 29162627)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

There were no financial disclosure.

Author information

Authors and Affiliations

  1. Kartal Dr. Lutfi Kirdar Training and Research Hospital, Department of Ophthalmology, Member of Turkey Ophthalmology Society, Member of Euretina, Fellowship of International Council Ophthalmology, Fellowship of European Board Ophthalmology, Health Science University, Istanbul, Turkey

    Hatice Selen Kanar

  2. Antalya Training and Research Hospital, Member of Turkey Urology Society, Fellowship of European Board Urology, Department of Urology, Health Science University, Antalya, Turkey

    Mahmut Taha Olcucu

  3. Department of Ophthalmology, Member of Turkey Ophthalmology Society, Sakarya Yenikent State Hospital, Sakarya, Turkey

    Ibrahim Ozdemir

Authors
  1. Hatice Selen Kanar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahmut Taha Olcucu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ibrahim Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hatice Selen Kanar.

Ethics declarations

Conflict of interest

Hatice Selen Kanar declares that she has no conflict of interest. Mahmut Taha Olcucu declares that he has no conflict of interest. Ibrahim Ozdemir declares that he has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Local Ethical Committee approval number is: B.30.2ATA.0.01.00.

Human and animal rights

Research involving human participants.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanar, H.S., Olcucu, M.T. & Ozdemir, I. Comparison of effects of tamsulosin and silodosin on subfoveal choroidal thickness and pupil size diameters in patients with prostatic hyperplasia. Int Ophthalmol 41, 3921–3927 (2021). https://doi.org/10.1007/s10792-021-01961-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-021-01961-4

Keywords

Search

Navigation